Navigation Links
GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America
Date:3/9/2011

CHICAGO, March 9, 2011 /PRNewswire/ -- GlobalCare Clinical Trials, Ltd, (GlobalCare) today announced its expansion into Latin America. GlobalCare provides selected clinical study visits at convenient locations – such as in the home or alternate settings – for study patients to support phase I-IV trials in a variety of therapeutic areas, genomics and personalized medicine in all age groups. GlobalCare's patient-centric service model provides faster patient recruitment, better protocol compliance and higher retention rates, while helping to decrease the cycle of time to biopharmaceutical development and speed delivery of life-enhancing products to market for the benefit of patients worldwide.

Regulatory-compliant services provided by GlobalCare include: global project management; study drug administration; blood and other biologic sample collection; clinical assessments; patient training and education; device management; source documentation; and data collection. In addition, the company offers central and local out-patient pharmacy services including storage and distribution, compounding and dispensing, cold chain logistics, and sourcing of commercial products and devices.

Serving the Globe

GlobalCare provides services in over 20 countries and maintains a centrally managed network of multilingual country coordinators who are trained and certified on Good Clinical Practice/International Conference on Harmonization (GCP/ICH) guidelines and have in-depth knowledge of local medical practices and country cultural attitudes. The network is augmented by an extensive pool of over 20,000 qualified local traveling physicians and nurses in the United States, Canada, Australia, Europe, Israel, and now Latin America. GlobalCare's model enables patients to participate in clinical trials regardless of study duration; frequency of visits; disease state; distance to site; and/or family, work or community commitments by conducting study vis
'/>"/>

SOURCE GlobalCare Clinical Trials, Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
3. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
4. Association of Clinical Research Organizations (ACRO) Welcomes Clinilabs and RPS as New Members
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
7. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
8. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
11. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... NEWPORT BEACH, Calif. , July 28, 2015 ... company, announced that it has hit a milestone ... Putty. Signafuse was FDA 510(k) cleared in early ... standalone use in posterolateral spine fusion procedures.  This ... graft products, as less than 6% of new ...
(Date:7/28/2015)... PARK, N.C., July 28, 2015  United Therapeutics Corporation ... results for the second quarter ended June 30, 2015. ... as compared to the second quarter of 2014 ... Jeffs, Ph.D., United Therapeutics, President and Co-Chief Executive ... to an increase in the number of patients ...
(Date:7/27/2015)... 27, 2015  Amgen (NASDAQ: AMGN ) today ... results on Thursday, July 30, 2015, after the close ... followed by a conference call with the investment community ... Amgen will be Robert A. Bradway , chairman ... senior management team. Live audio of the ...
(Date:7/27/2015)... ... July 27, 2015 , ... This ... industry.The report provides a basic overview of the industry including definitions, classifications, applications ... markets including development trends, competitive landscape analysis, and key regions development status. Development ...
Breaking Biology Technology:Revolutionary Bone Graft Exceeds Expectations 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11Amgen Announces Webcast of 2015 Second Quarter Financial Results 22015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3
... Dilon Technologies, makers of,a gamma imaging system optimized ... to the position of President and Chief Executive,Officer., ... medical device industry,having held a number of senior positions ... health care corporation he ran as,CEO for a number ...
... QuoNova LLC, which is,88.7% owned by XL ... data indicating high efficacy of selected Quorum ... MRSA (methicillin-resistant,Staphylococcus aureus) strains and fungal organisms ... strategy is to develop and commercialize its,proprietary ...
... finds patients with gene variant drink less, ... genetic makeup often,plays a role in determining ... Now new evidence-based research also shows a ... dependence., Investigators participating in the National ...
Cached Biology Technology:Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ' ... Major Weapon in the Battle Against Cancer' 2QSB Anti-Virulence Platform Inhibits Biofilm Formation by Staphylococcus Aureus MRSA and Candida sp 2QSB Anti-Virulence Platform Inhibits Biofilm Formation by Staphylococcus Aureus MRSA and Candida sp 3QSB Anti-Virulence Platform Inhibits Biofilm Formation by Staphylococcus Aureus MRSA and Candida sp 4DNA Predicts Reaction to Drug That Fights Alcohol Dependence 2
(Date:7/7/2015)... Conn. , July 7, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces a revised version ... this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the cards ...
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
(Date:6/25/2015)... -- According to a new market ... Technology, Material (Optical Prism, Piezoelectric, Capacitive & Adhesives), ... & Geography - Global Forecast to 2014 - ... expected to reach $14,500.07 Million by 2020, at ... 76 market Tables and 109 Figures spread through ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... New research on the reproductive habits of zebrafish offers ... tissues. The research team previously noticed that male zebrafish ... Their latest findings, publishing in the October 14 issue ... reveal the basis for this sex-specific regenerative deficiency: structures ...
... that river otters in Central Illinois are being exposed to ... U.S. in the 1970s and ,80s. Their analysis ... . The Illinois Department of Natural Resources collected 23 ... incidentally killed (hit by cars or accidentally caught in traps, ...
... a long time, it was thought impossible to isolate ... has achieved this elusive goal. Scientists Joana Meyer, from ... Prof. Bruce McDonald, and Laurent Cartier of the Swiss ... succeeded for the first time in extracting trace amounts ...
Cached Biology News:Sex over survival: Reproductive trait in fish impedes tissue regeneration 2Illinois river otters exposed to chemicals banned decades ago 2Illinois river otters exposed to chemicals banned decades ago 3A bad break for fake pearls 2
... thermostable DNA polymerase purified from the Thermus ... developed by Kaledin (1,2,3) for the isolation ... from thermophilic bacteria. Amplification of DNA fragments ... with this enzyme. The enzyme has both ...
HLA-DRbeta (DA2)...
... Antibody to Cytokeratin 5 / 6 ... molecular weight, basic type of cytokeratin expressed ... cell layers of stratified epithelia as well ... mesothelial cells and mesothelioma. Cytokeratin 6 (56 ...
...
Biology Products: